imacregeneration.com

(“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces it completed the first infusion of its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells in its Phase 1 clinical trial for the treatment of bradykinesia, or the gradual slowing and loss of spontaneous body movement, due to Parkinson’s disease. The Phase 1 clinical trial, consisting of a 15-patient dose escalation safety and tolerability study, will be conducted at three of IMAC’s clinical centers in Chesterfield, Missouri, Paducah, Kentucky, and Brentwood, Tennessee. The trial will be divided into three groups: (1) five patients with bradykinesia due to Parkinson’s disease will receive a low dose, intravenous infusion of stem cells, (2) five patients will receive a medium intravenous dose, and (3) five patients will receive a high intravenous dose. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers’ requirements, and its ability to protect its intellectual property.

IMAC Successfully Treats the 5 Major Causes of Shoulder Pain Shoulder pain can be caused by a wide variety of issues. IMAC Regeneration focuses on non-surgical, non-opioid treatments including regenerative medicine techniques like platelet rich plasma, regenerative cellular therapy, hands-on manual physical therapy, and chiropractic to restore function, movement, and get you back to doing the things that make you happy! Our medical team will collaborate to create a personalized treatment plan that may include platelet rich plasma, injections to unbrace tight muscles, skilled physical therapy to add stability then strength, and/or chiropractic care to keep the joint functioning properly. Speak with an Expert today about PRP for Shoulder Pain Fill out this form and tell us more about your shoulder pain.

(the “Company” or “IMAC”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced the United States Food and Drug Administration (the “FDA”) approved its investigational new drug application, which IMAC submitted in May 2020, for the use of umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual loss and slowing down of spontaneous body movement, due to Parkinson’s disease. The Company will now initiate enrollment of 15 patients for its Phase 1 trial to evaluate the safety and tolerability of the stem cell product acquired from technology developed by a major research university to treat patients with Bradykinesia due to Parkinson’s utilizing intravenous administration of Wharton’s jelly-derived mesenchymal stem cells. The Phase 1 trial will consist of three treatment protocols: five patients with bradykinesia due to Parkinson’s will receive a low dose intravenous infusion of stem cells, five patients will receive a medium dose intravenous infusion of stem cells and five patients will receive a high dose intravenous infusion of stem cells. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers’ requirements, and its ability to protect its intellectual property.

IMAC is now accepting Federal Employees Injured at Work IMAC Regeneration Centers is proud to be a provider in network with the Department of Labor Office of Workers Compensation Programs. If you or someone you love has covered benefits with the Federal Employees Compensation Act (FECA), Energy Employees Occupational Illness Compensation Program Act (EEOICPA) or Federal Black Lung Program (DCMWC), IMAC offers new medical treatments that can help repair acute injuries and effectively treat chronic pain and disease, without surgery or opioids. If you have been injured working for the federal government and have a new or existing claim with the Department of Labor FECA Program, IMAC provides specialized care through our team of physicians, physical therapists, occupational therapists, and chiropractors. IMAC locations across the country have a proven record of success treating injured USPS, active and retired Federal employees, and are proud to be a national leader in fighting the opioid epidemic by providing non-surgical pain and rehab centers in St. Louis, MO, Springfield, MO, Chicago, IL, Lexington, KY and Paducah, KY and Nashville, TN.